Clinical Trial

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Study acronym: TRIlogy-5
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
Protocol Amendment History 4 changes
notable Trial sites expanded: 29 -> 88 locations 2026-08-01
notable Trial sites expanded: 8 -> 29 locations 2026-07-07
critical Recruitment opened 2026-06-06
notable Trial sites expanded: 0 -> 8 locations 2026-06-06
Trial Details
NCT Number NCT07518186
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 700 participants
Start Date 2026-05-31
Primary Completion 2029-04-29 (estimated)
Study Completion 2032-12-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-31